New insights about myofibrillar myopathies: the role of metalloproteinases 2 and 9 in the pathogenesis

Alzira Alves de Siqueira Carvalho

Faculdade de Medicina do ABC

Vinicius Gomes Silva

Faculdade de Medicina do ABC

Roseli Corazzini

Faculdade de Medicina do ABC

Alan Patricio Silva (✉ alanpatricio.fmabc@gmail.com)

Faculdade de Medicina do ABC <https://orcid.org/0000-0003-2918-0060>

Emmanuelle Lacene

Hopital Pitie-Salpetriere Departement de Neuropathologie

Research article

Keywords: MMP-2, MMP-9, Myofibrillar myopathy, muscle biopsy, metalloproteinase

Posted Date: January 15th, 2020

DOI: <https://doi.org/10.21203/rs.2.20954/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

There are few reports suggesting that gene expression and activation of various matrix metalloproteinases (MMPs) are deregulated. MMP-2 and MMP-9 represent the two MMPs, which degrade type IV collagen, the component of basement membrane.

Methods

We analyzed the involvement of gelatinases, MMP-2 and MMP-9, in the pathogenesis of myofibrillar myopathy (MFM). Muscle specimens from 23 patients well diagnosed with MFM, were immunostained by MMP-2 and MMP-9. We analyzed qualitatively the immunoexpression in three compartments: subsarcolemmal (SSC), intracytoplasmic (ICC) and perinuclear (PNC).

Results

95,7% and 100% samples showed MMP-2 and MMP-9 upregulation ICC, respectively. PNC showed MMP-2 (82,6%) and MMP-9 (8,7%) regulation ($p < 0.001$). SSC and ICC did not present statistical significance. There was no correlation between mutated gene and immunohistochemical pattern distribution.

Conclusion

Our results suggest that MMP-2 and/or MMP-9 could participate in the pathomechanism of MFM, causing damage of sarcomere and deposition of protein aggregates.

Background

Since the discovery of metalloproteinases and its functions in 1962, they have been identified as extracellular matrix (ECM) proteinases responsible for transforming the matrix and degrading its components [1]. However, the discovery of an intracellular function of MMP-2 challenged this idea corroborating that MMP-2 not only repairs the ECM but also acts intracellularly in ischemia-reperfusion in myocardium by degrading troponin I, contributing therefore, to cardiac dysfunction [1, 2, 3, 4].

Regarding the role of MMPs in some myopathies, there are few reports suggesting that stimulation of various MMPs and also gene expression is deregulated. Whilst MMP-2 and MMP-9 are likely involved in the pathology of dystrophin-deficient skeletal muscle [5, 6], MMP-9 is implicated in the inflammatory myopathies during the process of elimination of necrotic fibers and muscle degeneration and MMP-2 may be associated with the process of reconstruction of ECM during muscle regeneration and fiber growth [7, 8].

Myofibrillar myopathies (MFM), a heterogeneous group of hereditary or sporadic skeletal and cardiac muscle disorders of sarcomere, are still a challenge in terms of our understanding about the

pathogenesis [9]. Many different components are involved in the cascade of events occurring in muscle fibers in these disorders, as mutant proteins, a defective ubiquitin – proteasome system and oxidative stress [10]. Nevertheless, there are no previous studies correlating the activation of MMPs and MFM.

In order to determine other components engaged in this pathogenic process we decided to examine the involvement of the gelatinases MMP-2 and MMP-9 in muscle fibers in MFM.

Methods

Muscle biopsies from 23 well-characterized patients with a previous diagnosis of MFM were studied. The diagnosis was obtained by clinical findings, morphological and ultrastructural aspects of muscle biopsies, and genetic studies. Control muscles specimens from 4 patients showing minimal and no specific findings in muscle biopsy were concurrently examined. We collected demographic data (gender, age of onset and age of diagnosis), gene mutated and specific mutations in order to correlate them with immunocytochemistry results.

Single immunocytochemistry: Five-micrometer serial sections from muscle specimens, stored in a freezer at -80°, were incubated in acetone at 4 °C for 10 minutes, washed in 0.05 mol/L Tris-buffered saline (pH 7.5) for 15 minutes, and fixed for 30 minutes with a blocking reagent containing 2% bovine serum albumin and 5% normal goat serum or 5% horse serum. Sections were then incubated overnight at 4 °C with one of the following antibodies: goat polyclonal IgG against human MMP-9 (dilution 1:50; Santa Cruz, Santa Cruz, CA, USA) or rabbit polyclonal IgG against human MMP-2 (dilution 1:400; Chemicon, Temecula, CA, USA). These affinity-purified antibodies are well characterized and do not cross-react with each other. After being washed for 30 minutes in Tris-buffered saline, the sections were incubated with biotinylated goat anti-rabbit IgG for MMP-2 or biotinylated horse anti-goat IgG for MMP-9, followed by fluorescent isothiocyanate avidin D.

We analyzed qualitatively the MMP-2 and MMP-9 muscle immunoexpression from all patients, including controls by optic microscopy fluorescence in three different compartments – subsarcolemmal (SS), intracytoplasmic (IC), and perinuclear (PN) – classifying them as expressed (+) or no expressed (-). In order to correlate the histopathological and immunocytochemical findings, five-micrometer serial sections were also stained with hematoxylin and eosin simultaneously.

Statistical analysis

To compare the immunostaining pattern and its correlation with demographic and genetic data, we performed the McNemar non-parametric test. For the tests, we used the SPSS 17.0 softwares for Windows. The significance level used for the tests was 5%[11]. Qualitative variables were presented using absolute frequency and relative frequency. In order to compare MMP-2 and MMP-9 regulation among the genetic groups, the Chi-square test was used. The level of significance adopted in this analysis was $p < 0.05$. The statistical program used was Stata version 11.0.

Results

Demographic features and molecular diagnosis from these patients are shown in Table 1. Among the patients, gender distribution was 11 (47.8%) females and 12 (52.2%) males. In our sample, 19 out 23 patients (82.6%) were genetically identified – DES = 9 (39.1%), ZASP = 5 (21.7%), FLNC = 3 (13%), MYOT = 2 (8.7%) and CRYAB = 2(8.7%) – and in two we did not find mutation (NMF) (8.7%).

Table 1
Demographic, molecular and immunohistochemical findings.

Patient	Gender	Δ t Diag	Mutation	MMP-2 PN	MMP- 2 SS	MMP- 2 IC	MMP-9 PN	MMP-9 SS	MMP- 9 IC
1	F	0	FLNC	-	+	+	-	-	+
2	F	10	DES	-	+	+	-	-	+
3	F	19	DES	-	+	+	-	+	+
4	M	21	DES	-	+	+	-	+	+
5	M	14	NMF	+	-	-	-	+	+
6	M	4	NMF	+	-	+	-	-	+
7	M	20	NMF	+	-	+	-	-	+
8	M	9	ZASP	+	-	+	-	-	+
9	F	5	MYOT	+	-	+	-	+	+
10	F	14	FLNC	+	-	+	-	+	+
11	M	25	ZASP	+	-	+	-	+	+
12	F	6	NMF	+	-	+	-	+	+
13	M	32	NMF	+	-	+	-	+	+
14	M	7	DES	+	-	+	+	+	+
15	M	10	DES	+	+	+	-	+	+
16	F	18	DES	+	+	+	-	+	+
17	M	14	NMF	+	+	+	-	+	+
18	F	8	ZASP	+	+	+	-	+	+
19	F	0	DES	+	+	+	-	+	+
20	M	7	ZASP	+	+	+	-	+	+
21	F	34	NMF	+	+	+	-	+	+
22	F	8	DES	+	+	+	+	+	+
23	M	20	FLNC	+	+	+	-	+	+

Legend: MMP: metalloproteinase; Δ t Diag: interval between age onset and diagnosis; NMF: no mutation found; PN: perinuclear; SS: subsarcolemmal; IC: Intracytoplasmic; -: downregulated; +: upregulated; NS: no symptoms.

Patient	Gender	Δt Diag	Mutation	MMP-2 PN	MMP-2 SS	MMP-2 IC	MMP-9 PN	MMP-9 SS	MMP-9 IC
Total (%)				82,6	56,5	95,7	8,7	78,3	100,0
Legend: MMP: metalloproteinase; Δt Diag: interval between age onset and diagnosis; NMF: no mutation found; PN: perinuclear; SS: subsarcolemmal; IC: Intracytoplasmic; -: downregulated; +: upregulated; NS: no symptoms.									

The age of diagnosis varied from 22 to 72 years (mean: 53.3 years; median: 56 years). The age of onset of symptoms ranged from 0 to 66 years (mean: 40.1 years; median: 41 years). The interval between the beginning of symptoms and the diagnosis varied from 0 to 34 years (mean: 13.3; median: 10).

The MMP-2 and MMP-9 muscle immunoexpression pattern distributions are presented in Table 1 and Graphic 1. It should be noted that both MMPs have a constitutive expression in endomysial blood vessels including control samples. There was no correlation between the immunoexpression pattern distribution and the duration of symptoms ($p > 0.05$). Most patients showed MMP-2 and MMP-9 expression (+) in the IC compartment (95.7% and 100%, respectively). The control group showed no expressed (-) in all 4 samples. (Fig. 1).

In terms of MMP-2 and MMP-9 expression, PN compartment showed a significant difference between MMP-2 expressed (82.6%) and MMP-9 expressed (8.7%) ($p < 0.001$). In contrast, SS and IC compartments did not present statistical significance between MMP-2 and 9 expression (Graphic 1, Table 1) however, the protein aggregates showing expression (+) varied from one patient to another. In addition, the same protein aggregate was expressed by MMP-9 but not by MMP-2, and vice-versa in the same section (Fig. 2b). Also, the immunodistribution of MMPs were similar in most patients in relation to different genetic groups (FLNC, DES, MYOT, ZASP, CRYAB and NMF) ($p > 0.05$).

Discussion

Our study was the first one to analyze the possibility of MMPs be involved in the pathogenesis of MFM. Interestingly, the results showed that MMP-2 and 9 are expressed in different compartments of skeletal muscle while in control muscles they were not demonstrated (Fig. 1).

We believe that both MMPs may participate actively in the pathological cascade leading to muscle membrane injury. MMP-9 comes from extracellular space into intracellular space and MMP-2 comes from intracellular space into extracellular space (Figs. 1, 2a). According to previous reports, MMP-2 is demonstrated in several subcellular compartments, including the thin and thick myofilaments, close to the Z disks of the cardiac sarcomere, the cytoskeleton, nuclei, mitochondria, and caveolae [4, 12]. Several intracellular processes are related to MMP-2 as cleaving specific proteins inside of myocytes thereafter reducing contractile function [4].

Particularly, MMP-2 presented significant expression (+) in the PN compartment ($p < 0.001$) in relation to MMP-9. By contrast, MMP-9 expression (+) was predominantly in the SS compartment demonstrating a possible influence of this gelatinase in ECM. In relation to IC compartment, our results were intriguing: both MMPs were expressed (+) in different regions of sarcoplasm. The same protein aggregate was expressed (+) by MMP-9 but not by MMP-2, and vice-versa in the same section (Fig. 2b).

So, there would be another component of cell signaling that could be part of the protein aggregate deposit and MMPs expressed would be just an epiphenomenon? Or why not, those MMPs expressed (PN, IC and SS) could not be protection factor to muscle fiber?

The mutations of known genes responsible for MFM will lead to an absence or dysfunction of coded proteins, causing mechanical instability of the sarcomere and, consequently, injury to the subcellular fiber compartments (ECM, sarcolemma, sarcoplasm, nucleus, and endoplasmic reticulum). The mechanical stress due to this instability would lead to MMP-2 upregulation with consequent destruction of the sarcomere, causing accumulation of proteins in the sarcoplasm (aggregates).

Conclusion

This study was the first one to analyze the role of MMPs in the pathogenesis of MFM. Our results showed that MMP-2 and 9 are expressed in different compartments of skeletal muscle while in control muscles they were not demonstrated. Therefore, they could participate in the pathomechanism of MFM, causing damage of sarcomere and deposition of protein aggregates.

More studies are necessary to clarify this new concept. Our study provides only preliminary qualitatively data about the role of MMPs in order to better understand the pathogenesis of this set of disorders.

Declarations

Ethics approval and consent to participate

Written informed consent for muscle analysis and clinical data publication were obtained from all the recruited patients when primary diagnostic procedures were performed, with explicit consent for future use for research purposes, according to the Declaration of Helsinki and the study was approved by our local Ethics Committee. The study was performed at Laboratoire de Pathologie musculaire – Risler; Institution Pitié-Salpêtrière, GH, 75013 Paris, France in accordance with the ethics committee of Pitié-Salpêtrière Hospital.

Consent for publication

Not applicable.

Availability of data and material

The datasets used and / or analyzed during the current study will be available from Professor Alves de Siqueira Carvalho on a reasonable request

Competing interests

None of the authors has any conflict of interest to disclose

Funding

Not applicable

Authors' contributions

All authors have contributed to the work, agree with the presented findings. The article has not been published before nor is being considered for publication in another journal.

Acknowledgements

Not applicable

Abbreviations

1. DES: desmin
2. DMD: Duchene muscular dystrophy
3. ECM: extracellular matrix
4. FLNC: filamin C
5. IC: intracytoplasmic
6. MMP: matrix metalloproteinase
7. MFM: myofibrillar myopathy
8. MYOT: myotilin
9. NMF: no mutation found
10. PM: polymyositis
11. PN: perinuclear
12. sIBM: sporadic inclusion body myositis
13. SS: subsarcolemmal
14. Zasp (LDB3): LIM DOMAIN-BINDING 3

References

1. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, SawickiG, SchulzR. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. *Circulation*.

- 2002;106: 1543–1549.
2. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-Lopez NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. *J Mol Cell Cardiol.* 2007; 43:429-36
 3. DeCoux A, Lindsey ML, Villarreal F, Garcia RA, Schulz R. Myocardial matrix metalloproteinase-2: inside out and upside down. *J Mol Cell Cardiol.* 2014; 77:64-72
 4. Schulz R. Intracellular Target of Matrix Metalloproteinase-2 in Cardiac Disease: Rationale and Therapeutic Approaches. *Annu Rev Pharmacol Toxicol.* 2007;47: 211-42
 5. Ogura Y, Tajrishi MM, Sato S, Hindi SM, Kumar A. Therapeutic potential of matrix metalloproteinase in Duchenne muscular dystrophy. *Front Cell Dev Biol.* 2014; 2: 1-11.
 6. Fukushima K, Nakamura A, Ueda H, Yuasa K, Yoshida K, Takeda S et al. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ). *BMC Musculoskelet Disord.* 2007 Jun 28; 8:54.
 7. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. *Neurology* 2000 Jan 11; 54(1): 65-71
 8. Schoser BGH, Blottner D, Stuerenburg HJ. Matrix metalloproteinases in inflammatory myopathies: enhanced immunoreactivity near atrophic myofibers. *Acta Neurol Scand* 2002; 105: 309-13
 9. Béhin A, Salort-Campana E, Wahbi K, Richard P, Carlier RY, Carlier P et al. Myofibrillar myopathies: State of the art, present and future challenges. *Rev Neurol (Paris).* 2015 Oct; 171(10): 715-29
 10. Ferrer, I; Olivé M. Molecular pathology of myofibrillar myopathies. *Expert Rev Mol Med.* 2008; 10 Sep 3;10: e25. doi: 10.1017/S1462399408000793.
 11. Rosner B. *Fundamentals of Biostatistics.* Boston. PWS Publishers. Second edition. 584pp.
 12. Carlson BM, Faulkner JA. The regeneration of skeletal muscle fibers following injury: a review. *Med Sci Sports Exerc.* 1983; 15(3): 187-98.

Figures

Figure 1. Immunolocalization of MMP-2 and 9

Figure 1

Immunolocalization of MMP-2 and MMP-9 Legend: MYOT mutation: A. H&E stain; B.MMP-2 upregulation IC (arrow head) and PN (arrow); C. MMP-9 upregulation SS (arrow) and IC (vacuole- arrow head); DES mutation: D. H&E; E. MMP-2 upregulation IC (arrow head) and PN (arrow); F. MMP-9 upregulation SS (arrow) and IC (arrow head)

Figure 2. Schematic view of the sarcomere structure and role of MMP-2 and MMP-9.

Figure 2

Schematic view of the sarcomere structure and role of MMP-2 and MMP-9. Legend: 2a. Schematic view of the sarcomere structure and its relationship with proteins of Z-line and presence of aggregates due a mutation (DES, ZASP, MYOT, BAG3, FLNC); 2b. MMP2- and MMP9 immunodistribution and its correlation with pathological findings in H&E stain (2b-1). MMP-2 upregulation PN (thick arrow) and IC (arrow); MMP-9 upregulation IC (including aggregates) (arrow head) and SS (thick arrow).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AlziraCarvalhoGraphic01MMP.tif](#)